Systemic sclerosis – dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings

  title={Systemic sclerosis – dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings},
  author={Michael Sticherling},
  journal={JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  • M. Sticherling
  • Published 1 October 2012
  • Medicine
  • JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Systemic sclerosis is a chronic inflammatory multiorgan disease belonging to the group of collagen‐vascular disorders. With a prevalence of 10/100,000 inhabitants it may be regarded a rather rare disease. Its etiology and pathogenesis have still not been elucidated in detail, especially with regard to the differential involvement of skin and the cause of the clinically heterogeneous disease courses. Various components of the vasculature, connective tissue as well as the immune system are… 

Systemic sclerosis and the gastrointestinal tract

  • I. Walecka
  • Medicine
    Przeglad gastroenterologiczny
  • 2017
Both limited and diffuse cutaneous SSc involve internal organs, with the involvement of the gastrointestinal tract as a leading cause of morbidity and treatment is mainly symptomatic with no disease-modifying drugs.

Pathology of Systemic Sclerosis

Systemic sclerosis is associated with a wide range of distinctive pathologic findings, including morpheaform skin thickening, pulmonary interstitial fibrosis and hypertension, renal thrombotic microangiopathy, and myocardial fibrosis.

Systemic scleroderma: An approach from plastic surgery

This pathology significantly affects the skin by causing lesions ranging from digital ulcers to facial atrophy, which are susceptible to management by plastic surgery.

European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes

Clinicians are provided with an overview of the diagnosis and treatment of localized scleroderma, systemic sclerosis including overlap syndromes of systemic sclerosis with diseases of the rheumatological spectrum.

The impact of systemic sclerosis on oral health

Education on oral hygiene and home-based orofacial physiotherapy may improve the oral status of patients with systemic sclerosis and improve the quality of life in SSc patients.

Retinoic acid for treatment of systemic sclerosis and morphea: A literature review

The treatment options for both systemic sclerosis and morphea are reviewed, and the potential of retinoic acid as a therapy and the supporting evidence from the literature are discussed, highlighting the previously published basic science and clinical studies investigating the role of retinosic acid in the treatment of sclerotic skin diseases.

Systemic therapy with calcitonin has positive clinical effects on systemic sclerosis in patients with cutaneous manifestations

Systemic calcitonin treatment seems to have positive clinical effects on SSc and contributes to relieving symptoms, especially in patients with cutaneous manifestations.

Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study

Hemodynamic characteristics and survival rates were similar in SSc-PAH patients with mild ILD and those without ILD, but the prognosis of different severity of ILD was poorer than that of IPAH patients.

Autoimmune skin diseases: Role of sex hormones, vitamin d, and menopause

Data support the idea that estrogen elevates autoantibodies and T helper 2 responses and promotes fibrosis by stimulating profibrotic interleukin-4 and transforming growth factor-β and fibroblast growth factor, all of which contribute to increased skin inflammation in rheumatic diseases in women.

Cartilage oligomeric matrix protein-induced complement activation in systemic sclerosis

Serum levels of COMP-C3b were found to be elevated in both dcSSc and lcSSc compared to healthy controls and decreased in patients on immunosuppressive therapy, suggesting that COMP does not drive complement activation in the skin in SSc.



The pathogenesis of systemic sclerosis.

Potential mechanisms underlying the vascular, autoimmune, and fibrotic points of dysregulation in systemic sclerosis are discussed.

Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies

Improvements in multiplex autoantibody assays will aid in the diagnosis and prognosis of the complications associated with systemic sclerosis and yield critical insights into the pathogenesis of, and suggest novel therapeutic targets for, this chronic, debilitating disease.

Systemic sclerosis - a systematic overview: part 1 - disease characteristics and classification, pathophysiologic concepts, and recommendations for diagnosis and surveillance.

A systematic overview of the classification concepts of scleroderma disorders, the epidemiologic and genetic burden, the complex pathophysiologic background, and the clinical features and the stage-dependent capillary microscopic features of SSc are summarized.

The many faces of scleroderma sine scleroderma: a literature review focusing on cardiopulmonary complications

Overall the clinical presentation is subtle and heightened clinical awareness is required to facilitate prompt recognition and treatment of ssSSc and the range and frequency of the clinical manifestations are described.

Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis

Digital vasculopathy is a serious complication of SSc contributing significant morbidity and often requiring hospital-based management, often requiring treatment with intravenous prostacyclin/CGRP.

Infectious disease as aetiological factor in the pathogenesis of systemic sclerosis.

The current state of knowledge of infectious risk factors in systemic sclerosis and the possible mechanisms by which infectious exposures might induce pathologic processes are reviewed.

Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database

The clinical distinction seemed to be superseded by an antibody-based classification in predicting some scleroderma complications, and the EUSTAR MEDS database facilitates the analysis of clinical patterns in SSc, and contributes to the standardised assessment and monitoring of SSc internationally.

[Clinical aspects of progressive systemic scleroderma (PSS). Multicenter studies of 194 patients].

Patients from five German Departments of Dermatology affected with progressive systemic scleroderma (PSS) were classified and examined, and the Raynaud symptom could be identified as being the main clinical symptom in 90% of the patients.

Mechanisms and consequences of fibrosis in systemic sclerosis

Overall, this is an exciting time for new therapies in SSc and advances are being made in synchrony with an improved understanding of the molecular and biochemical basis of the disease.

Prognostic markers for systemic sclerosis.

  • O. Meyer
  • Biology, Medicine
    Joint, bone, spine : revue du rhumatisme
  • 2006